These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18220738)

  • 1. Calcium sensing receptor activators: calcimimetics.
    Harrington PE; Fotsch C
    Curr Med Chem; 2007; 14(28):3027-34. PubMed ID: 18220738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics.
    Cook AE; Mistry SN; Gregory KJ; Furness SG; Sexton PM; Scammells PJ; Conigrave AD; Christopoulos A; Leach K
    Br J Pharmacol; 2015 Jan; 172(1):185-200. PubMed ID: 25220431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation and action of the calcium-sensing receptor.
    Drüeke TB
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V20-26. PubMed ID: 15284356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulators of the extracellular calcium receptor.
    Nemeth EF
    Drug Discov Today Technol; 2013; 10(2):e277-84. PubMed ID: 24050279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcimimetics: therapeutic potential in hyperparathyroidism.
    Cohen A; Silverberg SJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):734-9. PubMed ID: 12482739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
    Rybczyńska A; Hoppe A
    Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
    Davey AE; Leach K; Valant C; Conigrave AD; Sexton PM; Christopoulos A
    Endocrinology; 2012 Mar; 153(3):1232-41. PubMed ID: 22210744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.